Onyvax Information

View Top Employees from Onyvax

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of novel therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

Website	http://www.onyvax.com
Revenue	$16.2 million
Funding	$5.6 million
Employees	2 (2 on RocketReach)
Founded	1997
Phone	+44 20 8682 9494
Technologies	JavaScript , HTML , Google Analytics +9 more (view full list)
Industry	Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Therapeutics
Keywords	Therapeutic Antibodies, Cancer Therapies, Biological Therapies, Immunotherapy, Oncology, Novel Therapies, Tumor Targeting, Immune System, Cancer Treatment, Clinical Trials, Drug Development, Biotechnology, Pharmaceutical, Cancer Research, New Drugs, Precision Medicine, Targeted Therapy, Immuno-Oncology, Cell Therapy, Cancer Cells
Competitors	Johnson & Johnson, Merck & Co., Inc., Pfizer, Sanofi, GSK, AstraZeneca, Bristol Myers Squibb, Regeneron, Moderna Therapeutics, Novavax +31 more (view full list)
SIC	SIC Code 283 Companies, SIC Code 28 Companies
NAICS	NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies